---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-22-016015"
form_type: "8-K"
ticker: "OKUR"
cik: "0001637715"
company_name: "OnKure Therapeutics, Inc."
filed_at: "2022-01-24T23:59:59+00:00"
generated_at: "2026-06-27T16:15:30.394294+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.4
calibrated_materiality_score: 0.4
confidence: "high"
source: SEC EDGAR
---

# Reneo appoints Paul Hoelscher to board and audit committee chair; two directors exit

## Summary
- Paul Hoelscher appointed Class I director and Audit Committee Chair, effective Jan 20, 2022.
- Hoelscher receives $40k annual cash retainer plus $15k as Audit Committee Chair, and option for 35,000 shares vesting over 3 years.
- Lon Cardon will not stand for re-election at 2022 annual meeting due to new role at Jackson Laboratory.
- Kenneth Harrison resigned from board effective Jan 20 to focus on other endeavors; no disputes involved.

## SEC filing metadata
- accession: 0001193125-22-016015
- form_type: 8-K
- ticker: OKUR
- cik: 0001637715
- company_name: OnKure Therapeutics, Inc.
- filed_at: 2022-01-24T23:59:59+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.4
- calibrated_materiality_score: 0.4
- confidence: high
- sec_items: 5.02
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1637715/000119312522016015/0001193125-22-016015-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1637715/000119312522016015/d299391d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-22-016015
- JSON: https://secwatch.observer/filing/0001193125-22-016015.json
- Plain text: https://secwatch.observer/filing/0001193125-22-016015.txt

## Key facts
- Executive change
  Paul Hoelscher was appointed as Class I Director and Audit Committee Chair at OnKure Therapeutics, Inc..
  - Action: appointed
  - Role: Class I Director and Audit Committee Chair
  source text: On January 20, 2022, the Board of Directors (the “Board”) of Reneo Pharmaceuticals, Inc. (the “Company”), upon recommendation of the Nominating and Corporate Governance Committee of the Board, appointed Paul Hoelscher as (i) a Class I director of the Company, with a term of office expiring at the 2022 annual meeting of stockholders, (ii) a member of the Audit Committee of the Board (the “Audit Committee”) and (iii) Chair of the Audit Committee
  evidence_url: https://www.sec.gov/Archives/edgar/data/1637715/000119312522016015/0001193125-22-016015-index.htm
- Executive change
  Kenneth Harrison resigned as Director at OnKure Therapeutics, Inc..
  - Action: resigned
  - Role: Director
  source text: On January 20, 2022, Kenneth Harrison, Ph.D. resigned from the Board to focus on other endeavors.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1637715/000119312522016015/0001193125-22-016015-index.htm
- Executive change
  Lon Cardon departed as Class I Director at OnKure Therapeutics, Inc..
  - Action: will not stand for re-election
  - Role: Class I Director
  source text: On January 18, 2022, Lon Cardon, Ph.D. informed the Company that he will not stand for re-election as a member of the Board when his term as a Class I director expires at the Company’s 2022 annual meeting of stockholders.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1637715/000119312522016015/0001193125-22-016015-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.